Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Novo Nordisk ( (NVO) ) has shared an announcement.
Novo Nordisk announced the results of its STEP UP phase 3b trial, demonstrating that its semaglutide 7.2 mg treatment achieved a significant weight loss of 20.7% after 72 weeks compared to placebo in adults with obesity. The trial’s results strengthen the clinical profile of semaglutide for obesity treatment, complementing health benefits established with Wegovy®, and may influence future obesity treatments and Novo Nordisk’s market positioning.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. The company focuses on pioneering scientific breakthroughs in chronic diseases, particularly in diabetes, and aims to expand access to medicines and ultimately cure diseases. Novo Nordisk employs about 72,000 people across 80 countries and markets its products in approximately 170 countries.
YTD Price Performance: -5.08%
Average Trading Volume: 7,027,875
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $368.5B
See more data about NVO stock on TipRanks’ Stock Analysis page.
